Quantitative impact of immunomodulation versus oncolysis with cytokineexpressing virus therapeutics
Pages: 841  858,
Issue 4,
August
2015
doi:10.3934/mbe.2015.12.841 Abstract
References
Full text (423.8K)
Related Articles
Peter S. Kim  School of Mathematics and Statistics, University of Sydney, Sydney, NSW, Australia (email)
Joseph J. Crivelli  Weill Cornell Medical College, New York, NY, United States (email)
IlKyu Choi  Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimniro, Seongdonggu, Seoul 133791, South Korea (email)
ChaeOk Yun  Department of Bioengineering, College of Engineering, Hanyang University, Seoul, South Korea (email)
Joanna R. Wares  Department of Mathematics and Computer Science, University of Richmond, Richmond, VA, United States (email)
1 
T. Alarcón, H. M. Byrne and P. K. Maini, A cellular automaton model for tumour growth in inhomogeneous environment, J. Theor. Biol., 225 (2003), 257274. 

2 
N. Bagheri, M. Shiina, D. A. Lauffenburger and W. M. Korn, A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEKinhibition, PLoS Comput. Biol., 7 (2011), e1001085. 

3 
Z. Bajzer, T. Carr, K. Josić, S. J. Russell and D. Dingli, Modeling of cancer virotherapy with recombinant measles viruses, J. Theor. Biol., 252 (2008), 109122. 

4 
D. L. Bartlett, Z. Liu, M. Sathaiah, R. Ravindranathan, Z. Guo, Y. He and Z. S. Guo, Oncolytic viruses as therapeutic cancer vaccines, Mol. Cancer, 12 (2013), p103. 

5 
M. Biesecker, J. H. Kimn, H. Lu, D. Dingli and Z. Bajzer, Optimization of virotherapy for cancer, Bull. Math. Biol., 72 (2010), 469489. 

6 
R. Breban, A. Bisiaux, C. Biot, C. Rentsch, P. Bousso and M. L. Albert, Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response, Oncoimmunology, 1 (2012), 917. 

7 
D. M. Catron, A. A. Itano, K. A. Pape, D. L. Mueller and M. K. Jenkins, Visualizing the first 50 hr of the primary immune response to a soluble antigen, Immunity, 21 (2004), 341347. 

8 
Y. Chen, T. DeWeese, J. Dilley, Y. Zhang, Y. Li, N. Ramesh, J. Lee, R. PennathurDas, J. Radzyminski, J. Wypych, D. Brignetti, S. Scott, J. Stephens, D. B. Karpf, D. R. Henderson and D. C. Yu, CV706, a prostate cancerspecific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity, Cancer Res., 61 (2001), 54535460. 

9 
R. J. De Boer, M. Oprea, R. Antia, K. MuraliKrishna, R. Ahmed and A. S. Perelson, Recruitment times, proliferation, and apoptosis rates during the CD8(+) Tcell response to lymphocytic choriomeningitis virus, J. Virol., 75 (2001), 1066310669. 

10 
M. Del Vecchio, E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani and A. Anichini, Interleukin12: biological properties and clinical application, Clin. Cancer Res., 13 (2007), 46774685. 

11 
D. Dingli, C. Offord, R. Myers, K. W. Peng, T. W. Carr, K. Josic, S. J. Russell and Z. Bajzer, Dynamics of multiple myeloma tumor therapy with a recombinant measles virus, Cancer Gene Ther., 16 (2009), 873882. 

12 
R. Eftimie, J. L. Bramson and D. J. Earn, Interactions between the immune system and cancer: A brief review of nonspatial mathematical models, Bull. Math. Biol., 73 (2011), 232. 

13 
N. B. Elsedawy and S. J. Russell, Oncolytic vaccines, Expert Rev. Vaccines, 12 (2013), 11551172. 

14 
A. Friedman, J. P. Tian, G. Fulci, E. A. Chiocca and J. Wang, Glioma virotherapy: Effects of innate immune suppression and increased viral replication capacity, Cancer Res., 66 (2006), 23142319. 

15 
I. Ganly, V. Mautner and A. Balmain, Productive replication of human adenoviruses in mouse epidermal cells, J. Virol., 74 (2000), 28952899. 

16 
D. Hanahan and R. A. Weinberg, Hallmarks of cancer: The next generation, Cell, 144 (2011), 646674. 

17 
J. H. Huang, S. N. Zhang, K. J. Choi, I. K. Choi, J. H. Kim, M. G. Lee, M. Lee, H. Kim and C. O. Yun, Therapeutic and tumorspecific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL12 and 41BBL, Mol. Ther., 18 (2010), 264274. 

18 
C. Jogler, D. Hoffmann, D. Theegarten, T. Grunwald, K. Uberla and O. Wildner, Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species, J. Virol., 80 (2006), 35493558. 

19 
H. L. Kaufman and S. D. Bines, OPTIM trial: A Phase III trial of an oncolytic herpes virus encoding GMCSF for unresectable stage III or IV melanoma, Future Oncol., 6 (2010), 941949. 

20 
N. L. Komarova and D. Wodarz, ODE models for oncolytic virus dynamics, J. Theor. Biol., 263 (2010), 530543. 

21 
N. Kronik, Y. Kogan, M. Elishmereni, K. HaleviTobias, S. VukPavlović and A. Agur, Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models, PLoS ONE, 5 (2010), e15482. 

22 
F. Le Bœuf, C. Batenchuk, M. VähäKoskela, S. Breton, D. Roy, C. Lemay, J. Cox, H. Abdelbary, T. Falls, G. Waghray, H. Atkins, D. Stojdl, J. S. Diallo, M. Kærn and J. C. Bell, Modelbased rational design of an oncolytic virus with improved therapeutic potential, Nat. Commun., 4 (2013), p1974. 

23 
F. Le Bœuf, J. S. Diallo, J. A. McCart, S. Thorne, T. Falls, M. Stanford, F. Kanji, R. Auer, C. W. Brown, B. D. and Lichty, K. Parato, H. Atkins, D. Kirn and J. C. Bell, Synergistic interaction between oncolytic viruses augments tumor killing, Mol. Ther., 18 (2010), 888895. 

24 
D. Leopardo, S. C. Cecere, M. Di Napoli, C. Cavaliere, C. Pisano, S. Striano, L. Marra, L. Menna, L. Claudio, S. Perdona, S. Setola, M. Berretta, R. Franco, R. Tambaro, S. Pignata and G. Facchini, Intravesical chemoimmunotherapy in non muscle invasive bladder cancer, Eur. Rev. Med. Pharmacol. Sci., 17 (2013), 21452158. 

25 
H. L. Li, S. Li, J. Y. Shao, X. B. Lin, Y. Cao, W. Q. Jiang, R. Y. Liu, P. Zhao, X. F. Zhu, M. S. Zeng, Z. Z. Guan and W. Huang, Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors, Gene Ther., 15 (2008), 247256. 

26 
D. G. Mallet and L. G. De Pillis, A cellular automata model of tumorimmune system interactions, J. Theor. Biol., 239 (2006), 334350. 

27 
A. Melcher, K. Parato, C. M. Rooney and J. C. Bell, Thunder and lightning: Immunotherapy and oncolytic viruses collide, Mol. Ther., 19 (2011), 10081016. 

28 
W. Mok, T. Stylianopoulos, Y. Boucher and R. K. Jain, Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy, Clin. Cancer Res., 15 (2009), 23522360. 

29 
D. M. Rommelfanger, C. P. Offord, J. Dev, Z. Bajzer, R. G. Vile and D. Dingli, Dynamics of melanoma tumor therapy with vesicular stomatitis virus: Explaining the variability in outcomes using mathematical modeling, Gene Ther., 19 (2012), 543549. 

30 
S. J. Russell, K. W. Peng and J. C. Bell, Oncolytic virotherapy, Nat. Biotechnol., 30 (2012), 658670. 

31 
J. R. Tysome, X. Li, S. Wang, P. Wang, D. Gao, P. Du, D. Chen, R. Gangeswaran, L. S. Chard, M. Yuan, G. Alusi, N. R. Lemoine and Y. Wang, A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumorspecific immunity, Clin. Cancer Res., 18 (2012), 66796689. 

32 
M. J. van Stipdonk, E. E. Lemmens and S. P. Schoenberger, Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation, Nat. Immunol., 2 (2001), 423429. 

33 
H. VeigaFernandes, U. Walter, C. Bourgeois, A. McLean and B. Rocha, Response of naïve and memory CD8+ T cells to antigen stimulation in vivo, Nat. Immunol., 1 (2000), 4753. 

34 
Y. Wang, H. Wang, C. Y. Li and F. Yuan, Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery, Mol. Cancer Ther., 5 (2006), 362366. 

35 
D. Wodarz, Viruses as antitumor weapons: Defining conditions for tumor remission, Cancer Res., 61 (2001), 35013507. 

36 
D. Wodarz, Computational modeling approaches to studying the dynamics of oncolytic viruses, Math. Biosci. Eng., 10 (2013), 939957. 

37 
D. Wodarz and N. Komarova, Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection, PLoS ONE, 4 (2009), e4271. 

38 
J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. A. Kronenberg, B. U. Agunwamba, X. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. Horak, Q. Hong, A. J. Korman, J. M. Wigginton, A. Gupta and M. Sznol, Nivolumab plus ipilimumab in advanced melanoma, N. Engl. J. Med., 369 (2013), 122133. 

39 
S. Worgall, G. Wolff, E. FalckPedersen and R. G. Crystal, Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration, Hum. Gene Ther., 8 (1997), 3744. 

40 
J. T. Wu, D. H. Kirn and L. M. Wein, Analysis of a threeway race between tumor growth, a replicationcompetent virus and an immune response, Bull. Math. Biol., 66 (2004), 605625. 

41 
W. Zhang, G. Fulci, H. Wakimoto, T. A. Cheema, J. S. Buhrman, D. S. Jeyaretna, A. O. Stemmer Rachamimov, S. D. Rabkin and R. L. Martuza, Combination of oncolytic herpes simplex viruses armed with angiostatin and IL12 enhances antitumor efficacy in human glioblastoma models, Neoplasia, 15 (2013), 591599. 

Go to top
